Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Galapagos soars on $4-6 billion hopes for new drug

Strong results for an experimental drug that promises to disrupt the rheumatoid arthritis market lifted shares in Galapagos to an all-time high as analysts forecast multibillion-dollar sales.

Read More »

Takeda to Move U.S. Headquarters to Boston Area

Takeda Pharmaceutical will shutter the company’s Deerfield, Ill., U.S. headquarters and move the operations to Boston as the company consolidates operations following the $62 billion acquisition of Shire. The Illinois facility employs about 1,000 people.

Read More »

Urovant Files for IPO to Raise $150 Million

Urovant Sciences, a Vivek Ramaswamy company under the Roivant umbrella, filed for an initial public offering (IPO) to raise $150 million.

Read More »

Orexo soars after winning opioid drug appeal against Teva

A U.S. appeals court revived Swedish pharmaceutical company Orexo AB’s lawsuit accusing a unit of Israel’s Teva Pharmaceutical Industries Ltd. of infringing a patent for the opioid addiction drug Zubsolv.

Read More »

U.S. appeals court invalidates Acorda patents on MS drug

A U.S. appeals court invalidated Acorda Therapeutics Inc. patents covering the multiple sclerosis drug Ampyra, opening the door to generic competition for the company’s flagship product.

Read More »

Elevian Launches to Join Numerous Companies Focused on Longevity and Aging

In another example of companies focused on aging-related diseases, Elevian launched with $5.5 million in seed funding.

Read More »

28-7 Therapeutics Raises $65 Million to Advance Tumor Suppressor Research

Cambridge, Mass.-based Twentyeight-Seven Therapeutics (28-7) completed a $65 million Series A financing.

Read More »

J&J to work with India on compensation for recalled hip implants

Johnson & Johnson said the company would work with the Indian government to compensate patients who had suffered from hip implants that were recalled by the U.S. healthcare firm eight years ago after data showed high failure rates.

Read More »

Akcea Therapeutics to cut about 10 percent of workforce

Akcea Therapeutics Inc. planned to cut its workforce by about 10 percent after the U.S. health regulator declined to approve the company’s Waylivra drug for treating a genetic disease that causes fat accumulation in blood.

Read More »

Boston Scientific Announces Agreement To Acquire Augmenix

Boston Scientific announced a definitive agreement to acquire Augmenix Inc., a privately held company that has developed and commercialized the SpaceOAR System, a therapy used to reduce common and debilitating side effects that men may experience after receiving prostate cancer radiotherapy.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

April 2019 Focus: Healthcare agency & network profiles, industry overview & awards, and more!


Ad Right Bottom